Opioid Drug Abuse Testing Key Topic at Congress
|
By LabMedica International staff writers Posted on 08 Jun 2017 |
Development of new diagnostic procedures for opioid drugs and augmenting communication pathways between laboratory, clinician, and patient are important topics that will be addressed at the July 30 to August 3, 2017, AACC Annual Meeting & Clinical Lab Expo (San Diego, CA, USA).
In the United States - according to data reported in the December 2016 issue of the journal Morbidity and Mortality Weekly Report - opioids accounted for more than two-thirds of all drug overdose deaths in 2015, 15.6% more than the previous year, and drug overdose deaths nearly tripled between 1999 and 2014.
While official agencies and medical groups recommend clinical laboratory tests to support efforts aimed at curbing opioid drug abuse, many physicians may not be fully equipped with the knowledge required to interpret this test data for their patients. To help in this regard, nationally recognized centers, such as the Mayo Clinic (Rochester, MN, USA) have entered the limelight.
Physician requests for assistance in interpreting pain management tests at the Mayo Clinic increased after the [U.S.] Centers for Disease Control and Prevention (Atlanta, GA, USA) issued guidelines in March 2016 recommending urine drug testing before starting patients on opioid therapy and for monitoring them afterward. This guideline and others are driving the testing, but also leading to more confusion in terms of which type of laboratory tests to use - for example, immunoassays versus definitive methods - which specific tests to include, the frequency, and how to interpret those tests.
To help out, the Mayo Clinic now deploys many tools to help providers navigate the nuances of drug testing. Mayo’s online test catalog includes a primer on interpreting drug tests for compliance, along with short “hot topic” videos and other online educational tools.
Other institutions are also rising to the challenge. Vanderbilt University (Nashville, TN, USA) for example, now makes it possible for physicians to request interpretative services at the time they order a test.
In response to the opioid crisis, discussions at the AACC Annual Meeting will emphasize that clinical labs and their physician clients need to work together to stay abreast of drug testing needs in their local communities.
Related Links:
AACC Annual Meeting & Clinical Lab Expo
Mayo Clinic
Centers for Disease Control and Prevention
Vanderbilt University
In the United States - according to data reported in the December 2016 issue of the journal Morbidity and Mortality Weekly Report - opioids accounted for more than two-thirds of all drug overdose deaths in 2015, 15.6% more than the previous year, and drug overdose deaths nearly tripled between 1999 and 2014.
While official agencies and medical groups recommend clinical laboratory tests to support efforts aimed at curbing opioid drug abuse, many physicians may not be fully equipped with the knowledge required to interpret this test data for their patients. To help in this regard, nationally recognized centers, such as the Mayo Clinic (Rochester, MN, USA) have entered the limelight.
Physician requests for assistance in interpreting pain management tests at the Mayo Clinic increased after the [U.S.] Centers for Disease Control and Prevention (Atlanta, GA, USA) issued guidelines in March 2016 recommending urine drug testing before starting patients on opioid therapy and for monitoring them afterward. This guideline and others are driving the testing, but also leading to more confusion in terms of which type of laboratory tests to use - for example, immunoassays versus definitive methods - which specific tests to include, the frequency, and how to interpret those tests.
To help out, the Mayo Clinic now deploys many tools to help providers navigate the nuances of drug testing. Mayo’s online test catalog includes a primer on interpreting drug tests for compliance, along with short “hot topic” videos and other online educational tools.
Other institutions are also rising to the challenge. Vanderbilt University (Nashville, TN, USA) for example, now makes it possible for physicians to request interpretative services at the time they order a test.
In response to the opioid crisis, discussions at the AACC Annual Meeting will emphasize that clinical labs and their physician clients need to work together to stay abreast of drug testing needs in their local communities.
Related Links:
AACC Annual Meeting & Clinical Lab Expo
Mayo Clinic
Centers for Disease Control and Prevention
Vanderbilt University
Latest AACC 2017 News
- Siemens Healthineers Showcases Atellica Solution at AACC 2017
- Ortho Clinical Diagnostics Highlights Immunodiagnostics at Clinical Expo
- Combating Infectious Diseases Key Focus of AACC
- World's First Fully Integrated LC-MS/MS Clinical Analyzer Unveiled
- Clinical Chemistry Analyzer Provides DAU Screening
- Diatron Displays New Hematology Analyzer at UAE Congress
- Microscan Demonstrates Advanced Technology at Scientific Meeting
- AACC Middle East to Be Held in Abu Dhabi
- AACC 2017 Focus on CRISPR and Futuristic Testing Devices
- Keynote Address to Focus on CRISPR/Cas9 Gene Editing
- Winner of Qualcomm Tricorder XPrize Unveiled at AACC
- Annual Meeting Offers Industry Education and Entertainment
Channels
Clinical Chemistry
view channel
New Machine-Learning Equation Improves LDL Cholesterol Assessment
Accurate assessment of low-density lipoprotein (LDL) cholesterol is central to cardiovascular risk management, yet calculation methods can underestimate values in some patients. Laboratories widely use... Read more
Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
Accurately identifying which cognitively healthy older adults will later develop impairment due to Alzheimer’s disease remains difficult, as brain scans and genetic testing provide only part of the risk picture.... Read moreMolecular Diagnostics
view channel
New Biomarker Helps Guide Combination Therapy for Treatment-Resistant Breast Cancer
Chemotherapy resistance hampers treatment of triple-negative breast cancer (TNBC), particularly in tumors with TP53 mutations. Identifying biomarkers that signal resistance while pointing to actionable... Read moreBlood-Based Gene Expression Test Detects Early Pancreatic Cancer
Pancreatic cancer remains difficult to detect at a curable stage and is associated with poor survival outcomes. In Japan, the five-year relative survival rate is 8.5%, while early-stage disease accounts... Read moreHematology
view channel
New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more
AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
Treatment selection for hematologic malignancies often requires clinicians to synthesize clinical histories, genomic alterations, prior therapies, and rapidly evolving drug options. These complex decisions... Read moreImmunology
view channel
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read more
Cell-Free Assay Detects Functional IgE for Food Allergy Diagnosis
Accurately distinguishing sensitization from clinically relevant food allergy remains a challenge for laboratories, as routine blood tests detect allergen-specific immunoglobulin E (IgE) but not its capacity... Read more
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read moreMicrobiology
view channel
Syndromic GI Panel Detects Cyclospora for Rapid Case Confirmation
U.S. health authorities have reported a rapid increase in cyclosporiasis since May 2026, with more than 1,600 confirmed infections and thousands of additional suspected cases under investigation.... Read more
Rapid Panel Identifies Gram-Negative Pathogens and Resistance Markers in Bloodstream Infections
Bloodstream infections require rapid identification of causative pathogens and resistance mechanisms to guide effective therapy. Delays in profiling gram-negative organisms, which are frequently associated... Read morePathology
view channel
AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
Myelodysplastic neoplasms, a group of blood cancers that primarily affect older adults, are challenging to stage and monitor, often requiring repeated bone marrow biopsies that can yield uncertain interpretations.... Read more
Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
Mapping the spatial distribution of disease-relevant molecules within tissue remains a diagnostic challenge, particularly before alterations are visible by conventional microscopy. In Fabry disease, a... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
Leica Biosystems, an operating company of Danaher, has entered into a definitive agreement to acquire privately held StatLab Medical Products from Linden Capital Partners and Audax Private Equity.... Read more









